Zelić Kerep, Ana http://orcid.org/0000-0001-9186-2586
Olivieri, Atillio
Schoemans, Helene http://orcid.org/0000-0002-7568-8239
Lawitschka, Anita http://orcid.org/0000-0002-4843-4735
Halter, Jörg http://orcid.org/0000-0003-4304-1956
Pulanic, Drazen
Dickinson, Anne
Greinix, Hildegard T.
Pavletic, Steven Z.
Schultz, Kirk R. http://orcid.org/0000-0002-0001-6438
Lee, Stephanie J. http://orcid.org/0000-0003-2600-6390
Wolff, Daniel
Article History
Received: 13 September 2021
Revised: 5 September 2022
Accepted: 16 September 2022
First Online: 13 October 2022
Competing interests
: DW received honoraria from Mallinckrodt, Novartis, Takeda, MACO, Behring, Incyte and Neovii. SL received research funding from Amgen, AstraZeneca, Incyte (also steering committee), Kadmon, Novartis, Pfizer, Syndax, Takeda. H.S. participated in advisory boards for Incyte, Janssen & Novartis; received speaker’s fees from Novartis, Incyte, Jazz Pharmaceuticals, Takeda and the BHS (Belgian Hematological Society); received travel grants from EBMT, CIBMTR, Celgene, Abbvie, Incyte & Gilead and research funding from Novartis and the BHS (Belgian Hematological Society); also has frequently served as a volunteer for the BHS (Belgian Hematological Society), EBMT (European Society for Blood and Marrow transplantation), CIBMTR (Center for International Bone Marrow Transplantation Research) and EUPATI (European Patient Academy). HG participated in advisory boards and as speaker in scientific meetings for the companies Novartis, Gilead, Takeda, Sanofi and Therakos. Other authors did not declare any competing interests.